This paper presents the first demonstration of GNP loading with selected FLT3 inhibitor drugs (midostaurin, sorafenib, quizartinib, and lestaurtinib) and their assessment as therapeutic agents against AML, inside living cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.